Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 1/23/23 → 1/23/25 |
Funding
- Bristol Myers Squibb Company: $42,896.00
MCC-23-LUN-131-BMS: Phase II Study of Induction Platinum Doublet in Combination with Nivolumab Followed by Surgery or Concurrent Chemoradiation in Unresectable Stage IIIA-C Non-Small Cell Lung Cancer (NSCLC)
- Zinner, Ralph (PI)